caa a22 4500 606237429 CHVBK 20210128101253.0 cr unu---uuuuu 210128e20150701xx s 000 0 eng 10.1007/s10272-015-0546-y doi (NATIONALLICENCE)springer-10.1007/s10272-015-0546-y Boscheck Ralf International Institute for Management Development (IMD), Ch. de Bellerive 23, 1001, Lausanne, Switzerland aut Intellectual Property Rights and the Evergreening of Pharmaceuticals [Elektronische Daten] [Ralf Boscheck] Escalating he althcare expenditures and the need to ensure access to affordable medicine in both emerging and emerged economies are fuelling calls to contain the so-called evergreening practices of drug producers around the world. But such practices are the necessary outcome of a system that responds to market incentives and appears to be already sufficiently controlled by established patentability standards and policies that determine patent term extension. The key issues surrounding current trade disputes lie deeper. This article examines the link between technological advances and intellectual property rights in general and the presumably special case of drug supplies. It focuses on strategies for extending the market exclusivity for pharmaceuticals products and evaluates safeguards against such evergreening. ZBW and Springer-Verlag Berlin Heidelberg, 2015 Intereconomics Springer Berlin Heidelberg 50/4(2015-07-01), 221-226 0020-5346 50:4<221 2015 50 10272 https://doi.org/10.1007/s10272-015-0546-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10272-015-0546-y text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Boscheck Ralf International Institute for Management Development (IMD), Ch. de Bellerive 23, 1001, Lausanne, Switzerland aut NATIONALLICENCE 773 0- Intereconomics Springer Berlin Heidelberg 50/4(2015-07-01), 221-226 0020-5346 50:4<221 2015 50 10272